127 related articles for article (PubMed ID: 29675946)
1. Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease.
Pierson SK; Stonestrom AJ; Shilling D; Ruth J; Nabel CS; Singh A; Ren Y; Stone K; Li H; van Rhee F; Fajgenbaum DC
Am J Hematol; 2018 Jul; 93(7):902-912. PubMed ID: 29675946
[TBL] [Abstract][Full Text] [Related]
2. Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease.
Rubenstein AI; Pierson SK; Shyamsundar S; Bustamante MS; Gonzalez MV; Milller ID; Brandstadter JD; Mumau MD; Fajgenbaum DC
Br J Haematol; 2024 Mar; 204(3):921-930. PubMed ID: 38168727
[TBL] [Abstract][Full Text] [Related]
3. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.
Gao YH; Liu YT; Zhang MY; Li SY; Fajgenbaum DC; Zhang L; Li J
Br J Haematol; 2024 May; 204(5):1830-1837. PubMed ID: 38356434
[TBL] [Abstract][Full Text] [Related]
4. TAFRO Syndrome: A Syndrome or a Subtype of Multicentric Castleman Disease?
Takai K
Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540266
[TBL] [Abstract][Full Text] [Related]
5. TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy.
Williams C; Phillips A; Aggarwal V; Slonim LB; Fajgenbaum DC; Karmali R
Case Rep Oncol; 2021; 14(3):1359-1365. PubMed ID: 34720942
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease.
Bustamante MS; Pierson SK; Ren Y; Bagg A; Brandstadter JD; Srkalovic G; Mango N; Alapat D; Lechowicz MJ; Li H; Van Rhee F; Lim MS; Fajgenbaum DC
Haematologica; 2024 Jan; ():. PubMed ID: 38205523
[TBL] [Abstract][Full Text] [Related]
7. Genetic basis for iMCD-TAFRO.
Yoshimi A; Trippett TM; Zhang N; Chen X; Penson AV; Arcila ME; Pichardo J; Baik J; Sigler A; Harada H; Fajgenbaum DC; Dogan A; Abdel-Wahab O; Xiao W
Oncogene; 2020 Apr; 39(15):3218-3225. PubMed ID: 32051554
[TBL] [Abstract][Full Text] [Related]
8. Immunology and targeted therapy in Castleman disease.
Tsunoda S; Harada T; Kikushige Y; Kishimoto T; Yoshizaki K
Expert Rev Clin Immunol; 2024 May; ():1-12. PubMed ID: 38785062
[TBL] [Abstract][Full Text] [Related]
9. Castleman disease.
Carbone A; Borok M; Damania B; Gloghini A; Polizzotto MN; Jayanthan RK; Fajgenbaum DC; Bower M
Nat Rev Dis Primers; 2021 Nov; 7(1):84. PubMed ID: 34824298
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): Factors to differentiate from IgG4-related disease.
Nishikori A; Nishimura MF; Fajgenbaum DC; Nishimura Y; Maehama K; Haratake T; Tabata T; Kawano M; Nakamura N; Momose S; Sumiyoshi R; Koga T; Yamamoto H; van Rhee F; Kawakami A; Sato Y
J Clin Pathol; 2024 Feb; ():. PubMed ID: 38378248
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus Treatment for TAFRO Syndrome.
Shirai T; Ichikawa S; Saegusa J
Biomedicines; 2024 May; 12(5):. PubMed ID: 38791031
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy.
Mukherjee S; Martin R; Sande B; Paige JS; Fajgenbaum DC
Blood Adv; 2022 Jan; 6(2):359-367. PubMed ID: 34535010
[TBL] [Abstract][Full Text] [Related]
13. A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria.
Zhang L; Dong YJ; Peng HL; Li H; Zhang MZ; Wang HH; Liu QH; Su LP; Zhong LY; Wu WJ; Huang L; Yan XJ; Fan L; Tang WJ; Li ZL; Bi LT; Li Y; Gao GX; Gao L; Liu TB; Wei YQ; Liu Y; Yu L; Zhou H; Sun CY; Qian WB; Zou DH; Zhang HL; Ding KY; Wang XB; Bai O; Huang WR; Chen B; Yang L; Song J; Gao D; Chen T; Luo J; Wang SY; Ma LM; Fajgenbaum DC; Li J;
Lancet Reg Health West Pac; 2023 May; 34():100720. PubMed ID: 37283978
[TBL] [Abstract][Full Text] [Related]
14. Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease.
Goodman AM; Jeong AR; Phillips A; Wang HY; Sokol ES; Cohen PR; Sicklick J; Fajgenbaum DC; Kurzrock R
Eur J Haematol; 2021 Dec; 107(6):642-649. PubMed ID: 34431136
[TBL] [Abstract][Full Text] [Related]
15. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.
van Rhee F; Rosenthal A; Kanhai K; Martin R; Nishimura K; Hoering A; Fajgenbaum DC
Blood Adv; 2022 Aug; 6(16):4773-4781. PubMed ID: 35793409
[TBL] [Abstract][Full Text] [Related]
16. Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling.
Rossi JF; Chiang HC; Lu ZY; Levon K; van Rhee F; Kanhai K; Fajgenbaum DC; Klein B
Front Immunol; 2022; 13():919489. PubMed ID: 35928820
[TBL] [Abstract][Full Text] [Related]
17. Single-cell landscape of idiopathic multicentric Castleman disease in identical twins.
Chan JY; Loh JW; Lim JQ; Liany H; Lee ECY; Lee JY; Kannan B; Lim BY; Guo Z; Lim K; Ha JCH; Ng CC; Ko TK; Huang D; Seow DYB; Cheng CL; Chan SH; Ngeow J; Teh BT; Lim ST; Ong CK
Blood; 2024 May; 143(18):1837-1844. PubMed ID: 38170173
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus is effective for refractory/relapsed idiopathic multicentric Castleman disease: A single-center, retrospective study.
Liu YT; Gao YH; Zhao H; Zhang MY; Duan MH; Li J; Zhang L
Ann Hematol; 2024 May; ():. PubMed ID: 38691144
[TBL] [Abstract][Full Text] [Related]
19. Can We Differentiate Between Primary Sjögren Syndrome and Idiopathic Multicentric Castleman Disease Based on the Characteristics of Pulmonary Cysts?
Zhou J; Zhang L; Liu X; Zhang M; Liu Z; Jin Y; Feng R; Shi J; Li J; Zhang W
J Thorac Imaging; 2024 Apr; ():. PubMed ID: 38624132
[TBL] [Abstract][Full Text] [Related]
20. Siltuximab administration results in spurious IL-6 elevation in peripheral blood.
Mango NA; Pierson SK; Sarmiento Bustamante M; Brandstadter JD; van Rhee F; Fajgenbaum DC
Am J Hematol; 2024 Jan; 99(1):E15-E18. PubMed ID: 37867418
[No Abstract] [Full Text] [Related]
[Next] [New Search]
